Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation.

ABSTRACT:

Background

Breast cancer (BC) is a leading cause of premature death in women and the most expensive malignancy to treat. Since the introduction of targeted therapies has resulted in changes to BC therapy practices, health economic evaluations have become more important in this area. Taking generic medications, Aromatase Inhibitors (AIs), as a case study, we conducted a systematic review of the recent economic evaluations of AIs for estrogen receptor-positive breast cancer patients and evaluated the quality of these health economic studies.

Objective

To systematically review and examine the quality of the available economic studies of AIs in estrogen receptor-positive breast cancer.

Methods

A literature search was performed using six relevant databases (MEDLINE, Embase

SUBMITTER: Althuwaibi MF 

PROVIDER: S-EPMC10294338 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature